Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

US Generic Drug Market 2017-2022: Patent Expiry of Blockbuster Drugs, Price Differential between Generics and Innovator Drugs, Incentives for Dispensing and Prescribing Generic Drugs - Research and Markets

Research and Markets
Posted on: 20 Apr 17

Research and Markets has announced the addition of the "US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report to their offering.

The US generic drug market has witnessed a transformation over the last three decades. From less than 20% of the total prescriptions, generic drugs now account for the majority of the total prescriptions dispensed in the United States.

During 2010-2016, the US generic drug market grew at a CAGR of more than 13% and currently represents a multibillion dollar industry. The biggest catalyst of this industry is the significantly lower price of generics compared to branded drugs. Although generics are chemically identical to their branded counterparts, they are typically sold at substantial discounts from the branded price.

This has enabled governments and third-party payers to save billions of dollars in healthcare expenditures and resulted in lower copayments for patients. Other factors such as patent expiration of blockbuster innovator drugs, ageing population and an increasing prevalence of chronic diseases have also acted as catalysts for this market.

Key Topics Covered:

1 Preface

2 Research Methodology and Market Definitions

3 Executive Summary

4 US Generic Drug Market - Introduction

5 Why is the US Generic Drug Market so Lucrative

6 Global Generic Drug Market

7 US Generic Drug Market

8 SWOT Analysis

9 US Generic Drug Market - Value Chain Analysis

10 Pricing Mechanism and Profit Margins at Various Levels of the Supply Chain

11 Porter's Five Forces Analysis

12 US Generic Drug Market- Competitive Landscape

13 Regulations in the US Generic Drug Industry

14 US Generic Drug Market: Key Success Factors

15 US Generic Drug Market: Road Blocks

16 Requirements for Setting Up a Generic Drug Manufacturing Plant

17 Key Company Profiles

- Actavis

- Dr Reddy's

- Endo Pharmaceuticals

- Hospira

- Lupin Pharmaceuticals

- Mylan

- Par Pharmaceuticals

- Sandoz

- Sun Pharma

- Teva

For more information about this report visit

View source version on

Business Wire

Last updated on: 20/04/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.